Doyle Wealth Management acquired a new position in GlaxoSmithKline plc (NYSE:GSK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,221 shares of the pharmaceutical company’s stock, valued at approximately $221,000.
Other large investors have also recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC increased its holdings in GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares during the last quarter. Field & Main Bank acquired a new position in GlaxoSmithKline in the fourth quarter worth approximately $132,000. First Dallas Securities Inc. acquired a new position in GlaxoSmithKline in the fourth quarter worth approximately $142,000. Advisory Services Network LLC increased its holdings in GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after buying an additional 788 shares during the last quarter. Finally, Waldron LP acquired a new position in GlaxoSmithKline in the third quarter worth approximately $203,000. Hedge funds and other institutional investors own 9.52% of the company’s stock.
A number of research firms recently commented on GSK. Kepler Capital Markets upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday. TheStreet downgraded GlaxoSmithKline from a “b-” rating to a “c” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, February 5th. ValuEngine downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $38.57.
Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $36.27 on Tuesday. The stock has a market capitalization of $90,462.29, a P/E ratio of 45.91, a price-to-earnings-growth ratio of 2.33 and a beta of 0.98. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. GlaxoSmithKline plc has a 12-month low of $34.52 and a 12-month high of $44.53.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.03. The firm had revenue of $10.14 billion during the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. equities analysts forecast that GlaxoSmithKline plc will post 2.82 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be given a dividend of $0.633 per share. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a yield of 6.98%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio is presently 258.23%.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/doyle-wealth-management-acquires-new-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.